Market
Highlights
According
to MRFR analysis, Human Immunodeficiency Virus (HIV) Drugs Market
Analysis is expected to register a CAGR of 5% during the forecast period
of 2019 to 2025 and was valued at USD 24 million in 2018.
HIV drugs aim to control the growth of the human immunodeficiency
virus (HIV), improve the patient’s overall immune system, and reduce/stop the
symptoms. The drugs used to treat HIV infection are antiretrovirals, which help
reduce the viral load and fight the infection.
The
growth of the global HIV drug market is driven by the increasing prevalence of
HIV infection, rising awareness of HIV treatment, and the launch of innovative
drugs. However, stringent regulatory policies for drug approval and product
recalls are expected to curb the growth of the global HIV drug market during
the assessment period. The global Human Immunodeficiency Virus (HIV) Drugs
Market Analysis is currently dominated by several market players. The key
players are involved in product launches and strategic collaborations to
strengthen their market positions.
Segmentation
The
global HIV drug market has been segmented based on type and end-user. The
market, based on type, has been divided into nucleoside reverse transcriptase
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs),
protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, integrase
inhibitors, post-attachment inhibitors, and pharmacokinetic enhancers. The drugs in these different segments differ with respect
to their mechanism of treating the HIV infection. The different approaches for
treatment are, inhibiting HIV’s reverse transcriptase, preventing HIV
maturation, and preventing the entry of the virus into the host cells, among
others. The global Human Immunodeficiency Virus (HIV) Drugs Market Analysis has
been segmented based on end-user, into hospitals & clinics, specialty
centers, and others. The hospitals & clinics segment is expected to hold
the largest market share due to an increasing number of hospitals.
Key Players
Some of the key players in the Global Human Immunodeficiency Virus
(HIV) Drugs Market Analysis are Boehringer Ingelheim International, GmbH
(Germany), Cipla Inc. (India), Merck & Co., Inc. (US), AbbVie Inc. (US),
Bristol-Myers Squibb Company (US), Teva Pharmaceutical Industries Ltd (Israel),
Gilead Sciences, Inc. (US), F.Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc.
(US), Aurobindo Pharma (India), Celltrion Healthcare Co., Ltd (South Korea),
and ViiV Healthcare (UK).
Regional
Analysis
The
market has been divided, by region, into Europe, the Americas, Asia-Pacific,
and the Middle East & Africa. The Americas holds the largest market share.
The Human Immunodeficiency Virus (HIV) Drugs Market Analysis in the Americas
has further been branched into North America and Latin America, with the North
American market divided into the US and Canada. Europe is expected to be the
second-largest market owing to factors such as product launches by key players.
The European Human Immunodeficiency Virus (HIV) Drugs Market Analysis has been
categorized as Western Europe and Eastern Europe. The Western European market
has further been classified as Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. The Human Immunodeficiency Virus (HIV) Drugs Market
Analysis in Asia-Pacific has been segmented into Japan, China, India, South
Korea, Australia, and the rest of Asia-Pacific. Due to the growing awareness
regarding the use of HIV drugs and the increasing incidence of HIV in the
region, the market in Asia-Pacific is expected to be the fastest-growing. The Human
Immunodeficiency Virus (HIV) Drugs Market Analysis in the Middle East &
Africa has been divided into the Middle East and Africa and is expected to hold
the least market share.
No comments:
Post a Comment